Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021
Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008 Feb;30(2):271-9. doi: 10.1016/j.clinthera.2008.02.005